title: [Hip Fracture--Epidemiology, Management and Liaison Service. Medicines that prevent hip fracture].
abstract: Based on the results of numbers of the clinical trials, the medicines that prevent hip fracture are alendronate, risedronate, and denosumab, which are all antiresorptive. Although currently evidence is not available, combination anabolic and antiresoprtive therapy using teriparatide and denosumab is expected to efficiently prevent hip fracture because such therapy increases hip bone mineral density more than either drug alone.
authors: Department of Orthopaedic Surgery, Shinshu University School of Medicine, Japan.
authors: Shigeharu
authors: S
authors: Uchiyama
mesh_terms: D015519:Bone Density / Q000502:physiology; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001842:Bone and Bones / Q000293:injuries*; D004359:Drug Therapy, Combination; D006620:Hip Fractures / Q000188:drug therapy* / Q000517:prevention & control*; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*
chemical_list: D050071:Bone Density Conservation Agents